Marinus Pharmaceuticals Inc. (MRNS) Financial Statements (2024 and earlier)

Company Profile

Business Address 5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:150,300240,551122,927139,98391,68272,725
Cash and cash equivalents120,572240,551122,927138,50990,94367,727
Short-term investments 29,716  1,4747394,998
Other undisclosed cash, cash equivalents, and short-term investments 12     
Receivables3,7996,3482,629   
Inventory, net of allowances, customer advances and progress billings2,41377    
Inventory2,41377    
Contract with customer, asset, after allowance for credit loss    1,646  
Other undisclosed current assets8,7345,4026,1224,6382,4521,215
Total current assets:165,246252,378131,678146,26794,13473,940
Noncurrent Assets
Operating lease, right-of-use asset     
Property, plant and equipment3,8434,2362,4991,9452,2651,294
Other noncurrent assets1,8192,9042,6632,2502,443 
Other undisclosed noncurrent assets      
Total noncurrent assets:5,6627,1405,1624,1954,7081,294
TOTAL ASSETS:170,908259,518136,840150,46298,84275,234
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26,86223,99719,33310,7298,0316,909
Accounts payable4,0034,4613,1262,2112,7632,472
Accrued liabilities22,85919,53616,2078,5185,2684,437
Debt11,551     
Restructuring reserve      
Other undisclosed current liabilities2,2111,02021,233   
Total current liabilities:40,62425,01740,56610,7298,0316,909
Noncurrent Liabilities
Long-term debt and lease obligation61,42371,01840,809   
Long-term debt, excluding current maturities61,42371,01840,809   
Liabilities, other than long-term debt1,4182,6821,9792,5343,042 
Accounts payable and accrued liabilities7851,3411,9792,5343,042 
Operating lease, liability6331,341   
Other undisclosed noncurrent liabilities50,67844,801    
Total noncurrent liabilities:113,519118,50142,7882,5343,042 
Total liabilities:154,143143,51883,35413,26311,0736,909
Temporary equity, carrying amount     28,200 
Equity
Equity, attributable to parent16,765116,00053,486137,19959,56968,325
Preferred stock  4,0434,3024,469  
Common stock555037378753
Additional paid in capital588,656542,428459,852444,622295,056249,727
Accumulated other comprehensive loss (20)    (2)
Accumulated deficit(571,926)(430,521)(410,705)(311,929)(235,574)(181,453)
Total equity:16,765116,00053,486137,19959,56968,325
TOTAL LIABILITIES AND EQUITY:170,908259,518136,840150,46298,84275,234

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues30,98925,47815,345   
Cost of revenue(1,434)(1,209)(1,478)   
Cost of goods and services sold   (1,478)   
Gross profit:29,55524,26913,867   
Operating expenses(161,040)(137,057)(110,798)(69,655)(54,422)(37,179)
Other undisclosed operating income    1,718  
Operating loss:(131,485)(112,788)(96,931)(67,937)(54,422)(37,179)
Nonoperating income (expense)9,437(342)1,667459309532
Investment income, nonoperating8,1132,35480496362533
Gain, foreign currency transaction, before tax   930   
Other nonoperating income (expense)1,324(2,696)657(37)(53)(1)
Interest and debt expense(16,895)(10,672)(2,582)   
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    3(8)(79)
Loss from continuing operations before equity method investments, income taxes:(138,943)(123,802)(97,846)(67,475)(54,121)(36,726)
Other undisclosed income (loss) from continuing operations before income taxes(4,000)107,375(930)   
Loss from continuing operations before income taxes:(142,943)(16,427)(98,776)(67,475)(54,121)(36,726)
Income tax expense (benefit) 1,538(3,389)    
Loss from continuing operations:(141,405)(19,816)(98,776)(67,475)(54,121)(36,726)
Loss before gain (loss) on sale of properties:(98,776)(67,475)(54,121)(36,726)
Other undisclosed net loss      
Net loss attributable to parent:(141,405)(19,816)(98,776)(67,475)(54,121)(36,726)
Preferred stock dividends and other adjustments    (8,880)  
Net loss available to common stockholders, diluted:(141,405)(19,816)(98,776)(76,355)(54,121)(36,726)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(141,405)(19,816)(98,776)(67,475)(54,121)(36,726)
Comprehensive loss:(141,405)(19,816)(98,776)(67,475)(54,121)(36,726)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(20)    94
Comprehensive loss, net of tax, attributable to parent:(141,425)(19,816)(98,776)(67,475)(54,121)(36,632)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: